• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

What to Look for in COPD Next Year

Slideshow

These brief summaries highlight key developments in COPD and how they are likely to affect patient management in the months and years ahead.

Related Content
Drug Duo Improves COVID-19 Outcomes: Daily Dose / image credit: ©New Africa/AdobeStock

New Drug Boosts COPD Lung Function, QoL Regardless of Severity: Daily Dose

Sydney Jennings
October 25th 2024
Article

Your daily dose of the clinical news you may have missed.

Single vs Multiple Inhaler Triple Therapy for COPD Could Triple Adherence, Persistence: International Data / image credit - inhalers: ©Orawan/stock.adobe.com

Single vs Multiple Inhaler Triple Therapy for COPD Could Triple Adherence, Persistence: International Data

Grace Halsey
October 11th 2024
Article

CHEST 2024: Combined data from 4 continents found consistently better adherence/persistence when COPD triple therapy was initiated with a single inhaler.

/ image credit lung tissue COPD: ©SciePro/stock.adobe.com

Early Identification, Treatment of COPD Reduces Exacerbations, Health Care Burden

Grace Halsey
October 10th 2024
Article

CHEST 2024. Initial treatment for people with COPD should begin early in the disease and leads to significantly reduced risk for exacerbations and inpatient treatment.

Ensifentrine, Novel PDE3, PDE4 Inhibitor, Improves Lung Function, QoL Regardless of COPD Severity imaged credit - lung disease concept: ©alesmunt/stock.adobe.com

Ensifentrine, Novel PDE3, PDE4 Inhibitor, Improves Lung Function, QoL Regardless of COPD Severity

Grace Halsey
October 9th 2024
Article

The combined bronchodilator/anti-inflammatory agent significantly improved lung function, symptoms and QoL in adults with moderate or severe airflow obstruction.

FDA Approves First-Ever Biologic Medicine for COPD: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves First-Ever Biologic Medicine for COPD: Daily Dose

Sydney Jennings
October 8th 2024
Article

Your daily dose of the clinical news you may have missed.

© EWaldenmarus/stock.adobe.com

Dupilumab Becomes First Biologic Approved in the US as Targeted Therapy for Adults with COPD

Grace Halsey
September 27th 2024
Article

Dupilumab represents the first new treatment approach for uncontrolled COPD in more than a decade and reduced disease exacerbations by 34% in clinical trials.

© 2024 MJH Life Sciences

All rights reserved.